# Prediction Model for Response to Biologics and Small Molecular Agent for UC

> **NCT05186623** · — · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 300 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Vedolizumab, Ustekinumab, or Tofacitinib

## Key facts

- **NCT ID:** NCT05186623
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186623, "Prediction Model for Response to Biologics and Small Molecular Agent for UC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05186623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*